Recent Advances in Zirconium-89 Chelator Development [PDF]
Molecules, 2018 The interest in zirconium-89 (89Zr) as a positron-emitting radionuclide has grown considerably over the last decade due to its standardized production, long half-life of 78.2 h, favorable decay characteristics for positron emission tomography (PET ...
Nikunj B. Bhatt +2 more
doaj +5 more sources
Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease [PDF]
EJNMMI Research, 2019 Background Orbital inflammatory diseases are a heterogenic group of conditions that often entail a difficult diagnostic process and many patients are treatment resistant.
Kamil G. Laban +3 more
doaj +6 more sources
Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation [PDF]
Biomedicines, 2023 This study highlights the use of 89Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys,
Ahmed M. A. Mostafa +5 more
doaj +5 more sources
Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate [PDF]
PharmaceuticalsDesferrioxamine B (DFO) is the clinical standard chelator for preparing zirconium-89 labeled antibodies. In the current study, the stabilities of a zirconium-89 labeled panitumumab (PAN; Vectibix®) with three different chelators (DFO, DFO*, and DOTA ...
Falguni Basuli +5 more
doaj +4 more sources
Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability. [PDF]
ACS Omega, 2022 We report the synthesis and evaluation of novel chelating agents for zirconium-89
Kang CS +10 more
europepmc +3 more sources
Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution [PDF]
Molecules, 2019 Zirconium-89 is a promising radionuclide for nuclear medicine. The aim of the present work was to find a suitable method for obtaining zirconium-89 solutions for radiopharmaceutical purposes.
Anton Larenkov +5 more
doaj +2 more sources
A generic 89Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography [PDF]
International Journal of Nanomedicine, 2017 Nan Li,1,2,* Zilin Yu,1,* Truc Thuy Pham,1,* Philip J Blower,1 Ran Yan1 1Division of Imaging Sciences and Biomedical Engineering, St Thomas’ Hospital, King’s College London, London, UK; 2Tianjin Key Laboratory for Modern Drug Delivery & ...
Li N, Yu Z, Pham TT, Blower PJ, Yan R
doaj +3 more sources
The Evaluation of (1R,4R,7R,10R)-α,α′,α″,α‴-Tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTMA) as a Chelator for Zirconium-89 [PDF]
MoleculesRecently, macrocycles such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) have been observed to form zirconium-89 (89Zr: t½ = 78.4 h, β+: 22.8%, Eβ+max = 901 keV; EC: 77%, Eγ = 909 keV)-complexes with excellent in vivo stability.
Darpan N. Pandya +4 more
doaj +2 more sources
Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective [PDF]
EJNMMI Radiopharmacy and ChemistryBackground Immuno-positron emission tomography (immuno-PET) imaging is emerging as a highly promising technique for the non-invasive diagnosis of a wide range of pathological conditions, particularly in oncology and immunology.
Julien Dubois +6 more
doaj +2 more sources
Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB® [PDF]
EJNMMI Radiopharmacy and Chemistry, 2020 Purpose The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in tumors but only becomes available for antibody binding in dead tumor cells.
Vasilios Liapis +6 more
doaj +2 more sources